The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Research projects by Cameron University chemistry students were among the 250 undergraduate oral and poster presentations featured at the recent American Chemical Society Southwest Regional Meeting in ...

Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin GroupMaria Sainz ...

Wa'el Hashad Wa'el Hashad, CEO, Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has ...

Third Quarter, Recent Business Highlights and Upcoming Milestones Neurodegenerative Diseases Portfolio Alzheimer's Disease PRX012 ... approximately 260 patients in the ASCENT clinical trials Poster ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease .

The platform presentation entitled, “The MSA Atrophy Index: A Marker of Clinical Progression in Multiple System Atrophy”, was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, ...

For more information, or to sign-up to volunteer, go to https://www.concernedforthehungry.org. Fall-La-Palooza event aims to ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...